Press Releases

Aurora BioPharma, Inc. to Present at OktoberINVESTfest 2015

‚Äč

CAMBRIDGE, MA - October 12, 2015 - Aurora BioPharma, Inc. announces its CEO, Robert Brooks, will present at OktoberINVESTfest 2015, the 4th Bavarian American Annual Investors Conference at the New York Academy of Sciences, New York City, Room 2, 2:50 - 3:15 pm EST, on October 13, 2015.

Keynote: Roger Kubarych, International Economic Advisor, Craig Drill Capital Economic, global and geopolitical challenges and opportunities facing investors today.

Selected panelists: for full list visit http://www.oktoberinvestfest.com/program/

On our VC panel, Imran Babar of Orbimed, Christina Bechhold of Samsung Global Innovation Center and Christian Noske of BMW iVentures, will discuss best practices for enabling innovation, from a VC perspective.

Roman Huber, CEO of Bayern Kapital, will divulge how U.S. companies can take advantage of the German Bavarian state venture capital funds.

Doug Jamison, CEO for Harris and Harris Group, a venture capital firm focusing on BIOLOGY+ and disruptive science, will discuss game changing and life changing advances in life sciences and technology.

Beth Rosellini, from Nuviant, a medical device developer that has recently expanded to Europe, will present her firm's experiences in building a transatlantic business.

‚ÄčAbout Aurora BioPharma, Inc.

Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. The Company is one a handful of companies with Chimeric Antigen Receptor T-cell therapy (CAR T) in clinical trials in solid tumor, and pre-clinical trials in liquid and solid tumor . Aurora's AU-105 has completed a Phase I clinical trial in Glioblastoma and Sarcoma. In a Phase I trial, AU-105 achieved its endpoint of safety, with strong signals of tumor killing efficacy response and significant extension of survival. The Company is planning with its CAR T cell agent AU-105, a randomized multisite Phase II Glioblastoma trial, and a Phase I intracranial injection trial. The company also has an equity interest in MedVax Technologies, Inc., its cancer vaccine, MX-225, a P53 dendritic cell vaccine, completed FDA Phase II clinical trials, in Small Cell Lung Cancer, and the company is planning a combination trial with a PD-1 antibody in lung cancer in collaboration with a major pharmaceutical company. Aurora's team is comprised of experienced research scientists and business professionals with successful track records in the industry.

About OktoberINVESTfest

OktoberINVESTfest is hosted by Invest in Bavaria -- the investment organization of the German state of Bavaria's Ministry for Economic Affairs, Media, Energy and Technology with 26 representative offices in its global network. The European Commission rates the city Europe's number one tech hub and an important region for biotech and medical devices. This year's OktoberINVESTfest will once again be held at New York Academy of Sciences, World Trade Center 7. The building is one of New York's LEED-certified green buildings representative of Bavaria's Energy Turn Around initiatives.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For media inquiries, please contact:

Candace Cobos

VP, Business Development & Public Relations

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA 02138

Tel: (617) 674-7718 - Fax: (617) 674-7701

Ingraham Building, 25 SE 2nd Avenue, Suite 504

Miami, FL 33131

Tel: (305) 371-2301 - Fax: (305) 371-2304

candace.cobos@aurorabiopharma.net - www.aurorabiopharma.net

New Paradigm in Cancer Immunotherapy

Source: Aurora BioPharma, Inc.